In a LinkedIn post, Anas Younes, Senior VP, Global Head of Hematology (Early and Late Stage), Oncology R&D at AstraZeneca recently wrote:
”Interesting report, although I disagree with some of the comments. Accelerated approval is a very important process to quickly bring impactful medicines to patients with unmet medical needs, such as cancer. Of course, there is always room for improvement.”
Source: Anas Younes/LinkedIn